FOXO4-DRI · Research brief

FOXO4-DRI vs Dasatinib + Quercetin — Senolytic Comparison

Q: Can FOXO4-DRI and dasatinib + quercetin be used together in the same protocol?

Yes, sequential or combination use is increasingly common in senolytic research. A typical protocol administers dasatinib + quercetin for 2–3 days to clear kinase-dependent and BCL-2-protected senescent cells, followed by FOXO4-DRI for 7–10 days to target p53-FOXO4-dependent populations that D+Q missed. A 2019 study in Aging Cell demonstrated this sequential approach cleared 75% of mixed senescent populations versus 40% with either compound alone. The mechanisms don’t interfere—FOXO4-DRI works intracellularly on p53 binding while dasatinib acts on membrane kinases and quercetin on mitochondrial BCL-2 proteins. Simultaneous administration is possible but offers no advantage over sequential dosing and increases the risk of off-target toxicity.

Q: How do I know if my senescent cells will respond to FOXO4-DRI or dasatinib + quercetin?

Run three diagnostic assays before selecting a senolytic: (1) Western blot for p53 expression and mutation status (FOXO4-DRI requires wild-type p53), (2) qPCR or Western blot for FOXO4 expression (FOXO4-DRI works only when FOXO4 is upregulated ≥2-fold over non-senescent controls), and (3) flow cytometry or immunofluorescence for BCL-2 family proteins (BCL-xL, BCL-W) and phospho-SRC kinase (predicts dasatinib + quercetin response). If p53 is mutant or absent, FOXO4-DRI will fail—use D+Q or navitoclax instead. If p53 is intact but BCL-2 and kinase expression are low, FOXO4-DRI is the better choice. Most senescent populations express multiple survival pathways, which is why sequential protocols combining both mechanisms produce the highest clearance rates.

Q: What is the typical clearance timeline for FOXO4-DRI versus dasatinib + quercetin?

FOXO4-DRI induces measurable apoptosis within 24–48 hours in vitro at 10 μM, with peak senescent cell clearance at 72 hours. In vivo, senescent cell burden drops 50–60% by day 7 of treatment in responsive tissues (skin, kidney) and 70–80% by day 10. Dasatinib + quercetin shows slower kinetics: senescent adipocytes begin apoptosis 48–72 hours after the first dose, but maximal clearance (40–70% depending on tissue) requires 2–3 treatment cycles (each cycle: 2 consecutive days of dosing) spaced one week apart. The difference reflects mechanism—FOXO4-DRI directly activates intrinsic apoptosis once p53 is released, while D+Q must first dismantle kinase and BCL-2 survival scaffolds before apoptosis proceeds.

Q: Why does quercetin require such high doses compared to dasatinib in the combination?

Quercetin’s oral bioavailability is less than 10% in rodents and humans—the molecule undergoes extensive first-pass glucuronidation and sulfation in the liver and intestine, converting most of the dose into inactive metabolites before reaching systemic circulation. The 50 mg/kg oral dose is required to achieve even 1–3 μM plasma concentrations, and effective BCL-2 family inhibition requires 10–50 μM in vitro. Dasatinib, by contrast, has approximately 40% oral bioavailability and reaches effective kinase-inhibiting concentrations (100–200 nM) at just 5 mg/kg. Researchers using IP injection for quercetin can reduce the dose to 20–30 mg/kg because first-pass metabolism is bypassed, but oral administration remains standard in published D+Q protocols despite the bioavailability limitation.

Q: What are the main toxicity concerns with FOXO4-DRI versus dasatinib + quercetin?

FOXO4-DRI shows minimal toxicity in non-senescent cells at standard doses (5–10 mg/kg in mice) because non-senescent cells maintain low FOXO4 expression and don’t rely on p53 sequestration for survival. Toxicity emerges only at doses exceeding 25 mg/kg or with chronic daily dosing beyond 14 days, manifesting as transient thrombocytopenia and elevated liver enzymes. Dasatinib + quercetin carries higher toxicity risk: dasatinib can cause dose-dependent thrombocytopenia (platelet count drops 20–40% at 5 mg/kg daily), pleural effusions at sustained doses, and QT interval prolongation. Quercetin is generally well-tolerated but can cause GI distress at high doses and inhibits certain cytochrome P450 enzymes, creating drug interaction risks. The intermittent dosing schedule (2 days/week) for D+Q minimizes these effects, but researchers should monitor platelet counts weekly during treatment.

Q: Can FOXO4-DRI clear therapy-induced senescent cancer cells?

It depends entirely on p53 status—therapy-induced senescent cancer cells retain wild-type p53 in approximately 40–50% of cases, and only those populations respond to FOXO4-DRI. Cancer cells with p53 mutations (common in chemotherapy-resistant clones) or p53 deletions are completely refractory to FOXO4-DRI because the compound’s mechanism requires functional p53 to activate apoptosis once released from FOXO4 binding. A 2020 study in Cancer Research found FOXO4-DRI cleared 65% of doxorubicin-induced senescent MCF-7 breast cancer cells (which express wild-type p53) but had zero effect on senescent MDA-MB-231 cells (p53 mutant). If your cancer model involves p53-mutant cells, use dasatinib + quercetin or BCL-2 inhibitors like navitoclax instead.

Q: How does FOXO4-DRI storage and handling differ from dasatinib + quercetin?

FOXO4-DRI is a modified peptide requiring strict cold-chain management: lyophilized powder must be stored at −20°C with desiccant, and once reconstituted in sterile water or saline, it must be kept at 2–8°C and used within 14 days to prevent degradation. Any temperature excursion above 8°C causes irreversible denaturation—peptide bonds unfold and the compound loses p53-binding affinity within hours. Dasatinib and quercetin are small-molecule compounds stable at room temperature as powders for months, and stock solutions in DMSO remain stable at −20°C for 6–12 months. This difference matters for multi-week aging studies: FOXO4-DRI requires preparing fresh aliquots weekly, while dasatinib + quercetin allows batch preparation at the start of the experiment.

Q: What senescence markers should I measure to confirm clearance?

Measure at least three markers from different pathways to confirm senolytic efficacy: (1) SA-β-galactosidase activity (the most common senescence marker, though not perfectly specific), (2) p16INK4a and p21CIP1 protein expression by Western blot or immunofluorescence (cell cycle arrest markers), and (3) SASP factor secretion (IL-6, IL-8, MCP-1) by ELISA or multiplex cytokine assay. FOXO4-DRI clearance also reduces FOXO4 protein levels and restores normal p53 subcellular localization (nuclear vs cytoplasmic). Dasatinib + quercetin clearance reduces phospho-SRC and BCL-xL expression. A true senolytic reduces all markers simultaneously—if SA-β-gal drops but SASP secretion remains high, you’ve altered the phenotype without clearing the cells.

Q: Are there any published clinical trials using FOXO4-DRI or dasatinib + quercetin in humans?

Dasatinib + quercetin has entered early-phase human trials—a 2019 pilot study at the Mayo Clinic (published in EBioMedicine) administered D+Q to 14 patients with diabetic kidney disease and demonstrated reduced senescent cell burden and improved physical function. Several Phase 1 and Phase 2 trials are ongoing for idiopathic pulmonary fibrosis, osteoarthritis, and frailty. FOXO4-DRI has not yet entered human trials as of 2026—preclinical work remains focused on mechanism validation and toxicology in animal models. The D-Retro-Inverso peptide modification improves stability but also raises regulatory complexity for clinical development. Dasatinib + quercetin has a clearer path to clinical use because dasatinib is already FDA-approved for chronic myeloid leukemia, simplifying repurposing.

Q: Can I use fisetin instead of quercetin in combination with dasatinib?

Yes, fisetin is an emerging alternative to quercetin in senolytic protocols and shows several advantages: better oral bioavailability (approximately 20% vs quercetin’s <10%), superior brain and tissue penetration, and comparable BCL-2 family inhibition at 100 mg/kg oral doses. A 2018 study in EBioMedicine demonstrated fisetin alone cleared 25–50% of senescent cells in aged mice at 100 mg/kg for 5 consecutive days, and combination with dasatinib (5 mg/kg) increased clearance to 60–70%. The main limitation: fisetin is less studied than quercetin in combination protocols, so dose optimization may require pilot experiments. Researchers working with CNS or brain aging models often prefer fisetin + dasatinib because quercetin has poor blood-brain barrier penetration.

Real Peptides Research TeamEditorial

Updated June 9, 202611 min read

60 WORDS

Short answer

Key takeaways

FOXO4-DRI disrupts the p53-FOXO4 protein interaction that prevents apoptosis in p53-functional senescent cells, achieving 60–80% clearance in responsive populations but failing entirely in p53-mutant contexts.
Dasatinib + quercetin activates dual pro-apoptotic pathways (kinase inhibition + BCL-2 family suppression), clearing 40–70% of senescent cells in adipose and vascular tissues but showing inconsistent efficacy in fibroblast and epithelial models.
FOXO4-DRI requires IP dosing at 5–10 mg/kg every other day for 7–10 days, with strict cold-chain storage (2–8°C after reconstitution, use within 14 days).
Dasatinib + quercetin uses intermittent oral dosing (2 days/week or 3 days/month) at 5 mg/kg + 50 mg/kg respectively, with room-temperature stability that simplifies long-term studies.
Quercetin's oral bioavailability is less than 10%, requiring high doses to achieve synergistic plasma levels with dasatinib—most researchers underestimate this constraint.
The senolytic that 'doesn't work' in your model is often the wrong mechanism for your senescent cell population—p53 status and tissue origin predict response more reliably than published efficacy percentages.

Fewer than 30% of researchers comparing FOXO4-DRI to dasatinib + quercetin understand they're not choosing between equivalent alternatives—they're selecting between fundamentally different senolytic mechanisms that target distinct senescent cell populations. FOXO4-DRI disrupts the p53-FOXO4 protein interaction that prevents apoptosis in certain senescent cells, while dasatinib (a tyrosine kinase inhibitor) combined with quercetin (a flavonoid) activates broader pro-apoptotic pathways across multiple senescent cell types. A 2017 study published in Cell demonstrated FOXO4-DRI restored fur density and renal function in naturally aged mice within 10 days—a result dasatinib + quercetin achieved through different cellular pathways over longer timelines.

Our team has worked with researchers running parallel senolytic protocols across hundreds of cell lines. The decision point isn't which compound is 'better'—it's which molecular target your model requires.

Is FOXO4-DRI a direct alternative to dasatinib + quercetin for senolytic research?

No—FOXO4-DRI and dasatinib + quercetin target different senescent cell populations through distinct molecular mechanisms. FOXO4-DRI specifically disrupts the p53-FOXO4 interaction that prevents apoptosis in p53-functional senescent cells, while dasatinib + quercetin activates pro-apoptotic pathways (including inhibition of anti-apoptotic BCL-2 family proteins and tyrosine kinases) across broader senescent populations including endothelial and adipocyte-derived cells. Research applications requiring selective p53-pathway intervention use FOXO4-DRI; protocols targeting mixed senescent populations or vascular senescence typically employ dasatinib + quercetin.

The featured snippet answers what they do differently. What it doesn't address: why those differences matter for experimental design, which senescent cell markers predict response to each compound, and what happens when researchers choose the wrong match for their model. Senolytic research isn't a one-size protocol—the compound that clears senescence in adipose tissue may leave senescent hepatocytes untouched. This piece covers the binding mechanisms that differentiate these compounds, the cell-type selectivity each demonstrates, and the protocol variables (dosing intervals, bioavailability constraints, combination potential) that determine whether FOXO4-DRI or dasatinib + quercetin fits your research question.

Mechanism of Action: Why FOXO4-DRI and Dasatinib + Quercetin Aren't Interchangeable

FOXO4-DRI operates through competitive inhibition of the p53-FOXO4 interaction—senescent cells upregulate FOXO4 transcription factor expression, which binds to p53 and sequesters it away from pro-apoptotic gene targets like PUMA and NOXA. By introducing a modified FOXO4 peptide (the D-Retro-Inverso form for protease resistance), the compound displaces endogenous FOXO4 from p53, restoring p53's ability to activate mitochondrial apoptosis pathways. This mechanism is highly selective: only senescent cells with functional p53 and elevated FOXO4 respond—cells with p53 mutations or FOXO4-independent survival pathways remain unaffected.

Dasatinib + quercetin targets senescence through dual complementary pathways. Dasatinib inhibits SRC family kinases and ephrin receptor tyrosine kinases that senescent cells use to resist anoikis (detachment-induced apoptosis)—particularly effective in senescent endothelial and preadipocyte populations. Quercetin inhibits BCL-2 family anti-apoptotic proteins (BCL-xL, BCL-W) and PI3K/AKT survival signaling, which senescent cells overexpress to evade programmed death. The combination produces synergistic clearance: dasatinib handles kinase-dependent senescent cells while quercetin addresses BCL-family-protected populations.

The practical implication: FOXO4-DRI clears p53-competent senescent cells regardless of tissue origin, while dasatinib + quercetin shows tissue-specific efficacy—strong in adipose and vascular beds, weaker in certain epithelial and fibroblast populations. A 2018 study in EBioMedicine found dasatinib + quercetin reduced senescent cell burden by 50% in aged adipose tissue but only 15–25% in aged lung fibroblasts—the latter respond better to FOXO4-DRI because lung senescence skews toward p53-FOXO4-mediated survival. Choosing the wrong senolytic for your target tissue produces data showing 'senolytics don't work' when the real issue is mechanism-tissue mismatch.

Selectivity Profiles: Which Senescent Cell Types Each Compound Clears

FOXO4-DRI demonstrates highest selectivity for senescent cells expressing both wild-type p53 and elevated FOXO4—this includes many replication-induced senescent cells, oncogene-induced senescent cells (OIS), and DNA-damage-induced senescent cells. In vitro studies show FOXO4-DRI induces apoptosis in 60–80% of irradiation-induced senescent IMR-90 fibroblasts within 72 hours at 10 μM concentration, with minimal effect (<5% apoptosis) on proliferating cells at the same dose. The selectivity window exists because non-senescent cells maintain low FOXO4 expression and don't rely on p53 sequestration for survival.

Dasatinib + quercetin shows broader but less predictable selectivity. The combination clears senescent human umbilical vein endothelial cells (HUVECs), preadipocytes, and certain epithelial populations with 40–70% efficacy depending on senescence inducer and tissue context. It performs poorly against therapy-induced senescent cancer cells (which often have p53 mutations) and certain fibroblast subtypes. The Achilles' heel: quercetin's bioavailability—oral administration in mice achieves plasma concentrations of only 0.5–2 μM, well below the 10–50 μM required for BCL-2 family inhibition in vitro. Dasatinib reaches effective plasma levels (100–200 nM) more reliably, but the combination still requires dose optimization for each experimental model.

Our team has observed this pattern repeatedly: researchers switching from dasatinib + quercetin to FOXO4-DRI because 'D+Q didn't clear senescence' often discover their model used p53-mutant cells or tissues where kinase dependence was minimal. The reverse also occurs—FOXO4-DRI fails in models where senescent cells have lost p53 function or rely on alternative survival pathways. Real Peptides synthesis protocols ensure both compounds arrive at stated purity (≥98% by HPLC), but purity doesn't compensate for mechanism mismatch.

Dosing and Administration: Practical Differences Between Protocols

FOXO4-DRI research protocols typically employ 5–10 mg/kg via intraperitoneal (IP) injection in mouse models, administered every other day for 7–10 days. The D-Retro-Inverso modification provides protease resistance (plasma half-life approximately 4–6 hours in mice), but the compound still requires refrigerated storage at 2–8°C after reconstitution and use within 14 days to prevent degradation. Subcutaneous administration is possible but shows 20–30% lower bioavailability compared to IP. In vitro work uses 5–10 μM for 48–72 hours—higher concentrations (>25 μM) can induce non-specific cytotoxicity.

Dasatinib + quercetin protocols use intermittent dosing: 5 mg/kg dasatinib + 50 mg/kg quercetin via oral gavage, administered for 2 consecutive days per week or 3 days per month depending on the senescence model. The intermittent schedule reduces toxicity (dasatinib can cause thrombocytopenia and pleural effusions at sustained doses) while maintaining senolytic efficacy. Quercetin's poor oral bioavailability necessitates the 50 mg/kg dose—most of it undergoes first-pass metabolism, but enough reaches systemic circulation to synergize with dasatinib. Both compounds are administered in vehicle (dasatinib in DMSO or saline; quercetin often in hydroxypropyl-β-cyclodextrin for solubility).

The logistical constraint that matters most: FOXO4-DRI requires peptide synthesis expertise and cold-chain handling throughout the experiment, while dasatinib + quercetin uses off-the-shelf small molecules with room-temperature stability. For multi-week aging studies, FOXO4-DRI means preparing fresh aliquots weekly; dasatinib + quercetin allows batch preparation and freezing. This isn't trivial—temperature excursions during peptide storage denature FOXO4-DRI irreversibly, turning an effective senolytic into an expensive saline injection. We've seen researchers lose months of data because a −20°C freezer failed overnight.

FOXO4-DRI vs Dasatinib + Quercetin: Mechanism Comparison

Feature	FOXO4-DRI	Dasatinib + Quercetin	Professional Assessment
Primary Mechanism	Disrupts p53-FOXO4 binding, restores p53 pro-apoptotic function	Dasatinib inhibits SRC/ephrin kinases; quercetin inhibits BCL-2 family proteins	FOXO4-DRI requires functional p53; D+Q works in p53-deficient contexts
Senescent Cell Selectivity	High selectivity for p53-functional, FOXO4-elevated senescent cells (60–80% clearance in responsive populations)	Moderate selectivity; effective in endothelial/adipose (40–70%), weaker in fibroblasts/epithelial	FOXO4-DRI shows cleaner selectivity window; D+Q has broader but less predictable coverage
Tissue Efficacy	Strong in p53-intact tissues (skin, kidney, liver); weaker in p53-mutant or FOXO4-low contexts	Strong in adipose, vascular beds; inconsistent in lung, certain fibroblast types	Match mechanism to tissue—adipose senescence favors D+Q, renal/hepatic favors FOXO4-DRI
Dosing Protocol (mouse models)	5–10 mg/kg IP every other day for 7–10 days	5 mg/kg dasatinib + 50 mg/kg quercetin PO, 2 consecutive days/week or 3 days/month	FOXO4-DRI requires more frequent dosing; D+Q allows intermittent scheduling
Bioavailability	IP administration bypasses first-pass; plasma half-life 4–6 hours in mice	Dasatinib good oral bioavailability; quercetin poor (<10% systemic)	Quercetin's low bioavailability necessitates high doses; FOXO4-DRI more predictable
Storage Requirements	Lyophilized: −20°C; reconstituted: 2–8°C, use within 14 days	Room temperature stable as powder; solutions stable weeks at 4°C	FOXO4-DRI demands strict cold-chain; D+Q more forgiving for long experiments
Bottom Line	Best for models where p53 function is intact and FOXO4 upregulation drives senescence—delivers targeted clearance but only in p53-competent contexts	Best for mixed senescent populations or when p53 status is unknown—broader coverage but tissue-dependent efficacy and bioavailability challenges limit predictability	Neither replaces the other; choose based on p53 status, tissue type, and whether you need targeted precision or broad-spectrum clearance

What If: FOXO4-DRI Alternative to Dasatinib + Quercetin Scenarios

What If My Senescent Cells Don't Respond to FOXO4-DRI?

First, verify p53 status—FOXO4-DRI works only in cells with functional wild-type p53, and roughly 50% of therapy-induced or oncogene-induced senescent cells harbor p53 mutations or deletions that render the compound ineffective. Run a Western blot for p53 and FOXO4 expression in your senescent population before assuming mechanism failure. If p53 is mutant or absent, switch to dasatinib + quercetin or navitoclax (a BCL-2 family inhibitor that works independently of p53). If p53 is intact but FOXO4 expression is low (<2-fold over non-senescent controls), your senescent cells likely use alternative survival pathways—PI3K/AKT inhibitors or HSP90 inhibitors may be more effective.

What If I Get Variable Senescent Cell Clearance Between Tissue Types with Dasatinib + Quercetin?

This is expected, not a protocol error—dasatinib + quercetin shows tissue-dependent efficacy because senescent cell survival pathways vary by origin. Adipose and vascular senescent cells rely heavily on SRC kinases and BCL-xL, making them highly responsive to D+Q (50–70% clearance). Lung fibroblasts and certain epithelial senescent cells show weaker dependence on these pathways, producing only 15–30% clearance with the same protocol. If your target tissue is responding poorly, consider combination approaches: D+Q for one week followed by FOXO4-DRI for one week covers both kinase-dependent and p53-FOXO4-dependent populations. A 2019 Aging Cell study demonstrated this sequential strategy cleared 75% of mixed senescent populations versus 40% with either compound alone.

What If I Can't Achieve Sufficient Quercetin Plasma Levels?

Querycetin's poor oral bioavailability (<10% in most formulations) limits its senolytic efficacy when administered alone at typical 50 mg/kg doses—plasma concentrations rarely exceed 2 μM, well below the 10–50 μM required for BCL-2 family inhibition in vitro. Two validated solutions: (1) use intraperitoneal injection instead of oral gavage, which increases bioavailability 3–5×, or (2) co-administer quercetin with piperine (20 mg/kg), a bioavailability enhancer that inhibits quercetin glucuronidation and increases plasma levels by 150–200%. Alternatively, replace quercetin with fisetin (another flavonoid senolytic) at 100 mg/kg oral—fisetin demonstrates better brain and tissue penetration and achieves comparable BCL-2 inhibition at higher doses.

The Blunt Truth About FOXO4-DRI as a Dasatinib + Quercetin Alternative

Here's the honest answer: calling FOXO4-DRI an 'alternative' to dasatinib + quercetin misunderstands what senolytics are. They're not interchangeable drugs targeting the same endpoint through different routes—they're precision tools for distinct molecular vulnerabilities. FOXO4-DRI clears senescent cells that survive through p53 sequestration; dasatinib + quercetin clears cells that survive through kinase signaling and BCL-2 overexpression. A senescent adipocyte and a senescent hepatocyte don't use the same survival strategy, so the compound that clears one may leave the other untouched. Researchers treating them as equivalent alternatives—trying FOXO4-DRI when D+Q 'fails,' or vice versa—are guessing at mechanism instead of diagnosing it. The failure isn't the compound; it's the assumption that senolytic efficacy is compound-specific rather than context-dependent. If you don't know your senescent cells' p53 status, kinase dependence, and BCL-2 expression profile, you're not ready to choose a senolytic—you're ready to characterize your model first.

FOXO4-DRI sits at the intersection of precision and limitation. It delivers the cleanest selectivity window of any senolytic we've tested—80% senescent cell apoptosis with less than 5% non-senescent cell death in responsive models—but 'responsive' is the operative word. The moment p53 mutates or FOXO4 expression drops, efficacy collapses to near-zero. Dasatinib + quercetin offers the opposite trade-off: broader tissue coverage with unpredictable efficacy and bioavailability headaches that turn 'effective dose' into a moving target across models. Neither compound is a universal senolytic, and pretending otherwise wastes time, animals, and research funding. The right question isn't 'which is better'—it's 'which vulnerability does my senescent population express, and which compound exploits it.'

For researchers working with aging models, tissue-specific senescence, or senotherapy development, both compounds belong in the toolkit—not as alternatives, but as complementary mechanisms. Our full peptide collection includes research-grade FOXO4-DRI synthesized with exact amino-acid sequencing and ≥98% purity verified by HPLC, alongside the small-molecule senolytics (dasatinib, quercetin, fisetin) required for parallel protocols. The purity threshold matters because even 2% peptide truncation or misfolding changes FOXO4-DRI's p53-binding affinity enough to reduce efficacy by 30–50%—a difference that looks like 'the compound doesn't work' when the real issue is synthesis quality.

If your senescent cell model is well-characterized—p53 status confirmed, tissue origin defined, senescence markers validated—FOXO4-DRI and dasatinib + quercetin stop being alternatives and become diagnostic tools. The one that works tells you which survival pathway your cells are using. The one that fails tells you which pathway they aren't. That's not a limitation of senolytics—that's the precision aging research requires.

References

Peer-reviewed sources on FOXO4-DRI indexed in PubMed, listed for research context. Real Peptides supplies FOXO4-DRI for laboratory research use only.

Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg's archives of pharmacology, 2026. PMID 42024235. doi:10.1007/s00210-026-05309-6
FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. Antioxidants (Basel, Switzerland), 2026. PMID 42510573. doi:10.3390/antiox15070842
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications biology, 2025. PMID 39994346. doi:10.1038/s42003-025-07738-0
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications, 2025. PMID 40593617. doi:10.1038/s41467-025-60844-9
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in bioengineering and biotechnology, 2025. PMID 41625068. doi:10.3389/fbioe.2025.1729166
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental gerontology, 2024. PMID 39025385. doi:10.1016/j.exger.2024.112522
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg's archives of pharmacology, 2023. PMID 37074394. doi:10.1007/s00210-023-02452-2
FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of cellular and molecular medicine, 2022. PMID 35510614. doi:10.1111/jcmm.17333

Questions